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Bisphosphonates (BPs) are widely used to treat bone diseases and also appear to possess direct antitumour activity. We have
previously reported that third-generation BPs such as zoledronic acid (ZOL) and minodronic acid (YM529) synergistically augment
the effects of anticancer agents in various cancer cells. Recently, we have also reported the antitumour effects of YM529 on murine
osteosarcoma cells. As YM529 has not been clinically available, we herein focused on the anti-osteosarcoma effects of ZOL which is
clinically available. In addition to ZOL alone, we evaluated the concurrent or sequential combined effects of ZOL with other
anticancer agents against murine osteosarcoma cell lines. ZOL showed almost same anti-osteosarcoma activity compared with
YM529 and more sensitive growth inhibitory effects against osteosarcoma cells than normal cells. Moreover, ZOL acted synergistically
in vitro when administered concurrently with paclitaxel (PAC) or gemcitabine (GEM), not only in wild-type osteosarcoma cells but
also in P-glycoprotein (P-gp)-overexpressing osteosarcoma cells, which were much less sensitive against each anticancer agent.
Furthermore, 24h of ZOL pretreatment significantly augmented the sensitivity of doxorubicin (DOX), PAC or GEM against
osteosarcoma cells. These findings suggest that combined administration of ZOL with other anticancer agents may improve the
osteosarcoma treatment.
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Osteosarcoma is a high-grade malignant bone neoplasm that
occurs in children and adolescents. Recently, the prognosis of
these patients has improved substantially owing to the develop-
ment of various adjuvant chemotherapies. However, these
chemotherapies are not fully effective and as a result, 20% of all
osteosarcoma patients still die owing to tumour metastasis (Link,
1993; Unni, 1996; Bacci et al, 2006). As a consequence, various new
osteosarcoma therapies have been investigated worldwide, with
many clinical trials performed on novel agents.
Bisphosphonates (BPs) are widely used to treat bone diseases
such as osteoporosis, which is caused by excessive bone resorption
or metastatic bone involvement (Fleisch, 2002). We have
previously reported that third-generation BPs such as zoledronic
acid (ZOL) and minodronic acid YM529 show direct antitumour
effects and synergistically augments the effects of anticancer agents
in various cancer cell lines (Kuroda et al, 2003; Kimura et al,
2004; Matsumoto et al, 2005; Segawa et al, 2005; Yuasa et al,
2005). Recently, several investigators have reported the anti-
osteosarcoma effects of third-generation BPs in vitro (Evdokiou
et al, 2003; Kubista et al, 2006; Kubo et al, 2006; Tenta et al, 2006)
and in vivo (Heymann et al, 2005; Ory et al, 2005). We have also
reported that YM175 and YM529 inhibit the growth of murine
osteosarcoma cell lines in a time- and dose-dependent manner by
preventing prenylation of small GTPases and might be subject to
multi-drug resistance mechanism in osteosarcoma cells (Horie
et al, 2006).
There are numerous reports concerning the combined effects of
third-generation BPs with anticancer agents in various cancer cell
lines. However, only Heymann et al (2005) reported the combined
effect of ZOL with ifosfamide in osteosarcoma cell lines. As YM529
has not been clinically available, we herein focused on the anti-
osteosarcoma effects of ZOL which is clinically available. In
addition to ZOL alone, we herein investigated the concurrent or
sequential combined effects of ZOL against two murine osteosar-
coma cell lines not only with commonly used agents for
osteosarcoma such as doxorubicin (adriamycin, DOX), cisplatin
(CDDP) and methotrexate (MTX) (Bacci et al, 2006) but also with
novel agents such as imatinib mesylate (IM), paclitaxel (PAC) and
gemcitabine (GEM) which have recently been analysed for
osteosarcoma treatment (Verweij et al, 2000; McGary et al, 2002;
Okuno et al, 2002).
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sMATERIALS AND METHODS
Reagents
ZOL (1-hydroxy-2-(1H-imidazole-1-yl) ethylidene-bisphosphonic
acid) and IM were obtained from Novartis Pharma AG (Basel,
Switzerland). DOX (from Kyowa Hakko Kogyo Co. Ltd., Tokyo,
Japan), CDDP (from Nihon Kayaku Co. Ltd., Kyoto, Japan), PAC
(from Bristol–Myers Squibb, New York, USA) and GEM (from Eli
Lilly KK, Kyoto, Japan) were provided by each company MTX,
verapamil and ethylenediaminetetracetic acid (EDTA) were
purchased from Sigma Aldrich (Tokyo, Japan). ZOL, DOX, IM
and PAC were dissolved in Ca
  Mg
  phosphate-buffered saline
(PBS). MTX was dissolved in 0.1 N NaOH and then further diluted
in PBS. All diluted solutions were stored at  201C. Appropriate
drug concentrations were made by dilution with fresh medium
immediately before each experiment.
Cell lines
MOS cell line was established from the murine osteosarcoma
model developed at Massachusetts General Hospital (Choi et al,
1979). P-glycoprotein (P-gp)-overexpressing cell line which was
established by stepwise increments of DOX, MOS/ADR was
generated as previously reported (Takeshita et al, 1996). Murine
osteosarcoma cell line, LM8 was established from the murine Dunn
osteosarcoma cell line (Asai et al, 1998). Normal human dermal
fibroblasts (NHDF) cell line was purchased from Kurabo (Osaka,
Japan). These cells were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 15mM HEPES buffer, 10% foetal
bovine seruman antibiotic solution of penicillin (100Uml
 1) and
streptomycin (100mgml
 1). Normal murine osteoblast cells were
isolated from murine skull bone as described elsewhere (Takahashi
et al, 1988). These cells were maintained in a-MEM supplemented
with 10% foetal bovine serum and an antibiotic solution of
penicillin (100Uml
 1) and streptomycin (100mgml
 1). All cells
were cultured at 371C in a fully humidified incubator with 5%
CO2. All experiments described were performed at least three times
using cells in the exponential growth phase.
Concurrent exposure to ZOL and other anticancer agents
Proliferation of the cell lines was determined using the methyl-
thiazol-diphenyl-tetrazolium (MTT) assay, as previously described
(Hansen et al, 1989). MOS, MOS/ADR or LM8 and osteoblast
or NHDF cells were cultivated in a flat-bottomed 96-well plate
(Greiner Labortechnik, Frickenhausen, Germany) at 5 10
3 and
1 10
4 cells per well, respectively in 100ml of medium and
incubated with various concentrations of ZOL alone or in
combination with other anticancer agents such as DOX, CDDP,
MTX, IM, PAC or GEM for 48h. The means of six data values for
each treatment were calculated. For all the cell lines, we evaluated a
linear relationship between the degree of proliferation and cell
number within the range of the experiment. Half-maximal
inhibition constants (IC50) were determined using the nonlinear
regression programme CalcuSyn (Biosoft, Cambridge, UK). To
investigate the effect of combining ZOL with other anticancer
agents, the MOS or LM8 cells were treated with six concentrations
(0.25, 0.5, 0.75, 1.0, 1.5 or 2.0 IC50) of ZOL alone and
ZOL combined with another anticancer agent. The fraction
affected (Fa) (i.e. Fa of 0.25 is equivalent to 75% viable cells)
and the combination index (CI) were calculated with CalcuSyn
(Chow et al, 2000). This method enables quantification of
synergism (CIo1) and antagonism (CI41) at different dose and
effect levels. Combination index calculations were made under the
assumption that the mechanisms of drug action were not mutually
exclusive.
Sequential exposure of cells to ZOL and other anticancer
agents
We next investigated the effect of a sequential exposure regime
with ZOL, followed by the other anticancer agents. MOS or LM8
cells were incubated in 96-well plates at a density of 1.5 10
3 in
100ml of medium per well for 24h, then incubated with 1.0mM ZOL
for MOS cells or 10mM ZOL for LM8 cells for 24h. After the
osteosarcoma cells were washed thrice in PBS, the second
anticancer agent was added to the respective wells. After a further
48h, the rate of growth inhibition was evaluated by MTT assay.
Data from three independent experiments were collected and the
Student’s t-test was used to evaluate the efficacy of sequential
treatment of ZOL and other agents and to compare the effects of
each anticancer agent alone. P-values of less than 0.05 were
considered statistically significant and were derived from two-
sided statistical tests.
Cell cycle analysis
To explore the possible mechanisms of combined effects of ZOL
and other agents, MOS or LM8 cells were analysed for cell cycle
alterations by staining with propidium iodide (Sigma Aldrich)
after exposure to ZOL and/or anticancer agents for 24h, as
previously described (Kimura et al, 1995). The stained nuclei were
analysed using a FACSCalibur flow cytometry (Becton Dickinson,
Japan). DNA histograms were created using Cell Questt software
for Apple Macintosh (Becton Dickinson).
RESULTS
Growth inhibitory effects of ZOL against murine
osteosarcoma cells
ZOL inhibited the growth of murine osteosarcoma cells dose
dependently, whereas in normal cells such as murine osteoblast
cells and human fibroblast cells, NHDF were much less sensitive to
ZOL. Growth of MOS cells was not inhibited by up to 1000mM
EDTA (Figure 1A). The IC50 values of ZOL for MOS, LM8,
osteoblast and NHDF cells after 48h exposure were 1.56, 7.36,
72.4 and 145.3mM, respectively. ZOL showed almost same anti-
osteosarcoma activity compared with YM529 (Table 1).
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Figure 1 Effect of ZOL on growth of cells. (A) The ability of ZOL to
inhibit the growth of the murine osteosarcoma MOS cells (K), murine
osteoblast cells (’) and human fibroblast cell line (&) was determined by
MTT assay. And also, that of EDTA to inhibit the growth of MOS cells ( )
was determined. The ability of DOX (B) and ZOL (C) to inhibit the
growth of the P-gp-overexpressing MOS/ADR cell line (J) and its parental
MOS cell line (K) was determined by MTT assay. MOS/ADR cell line was
4.4 times more resistant to DOX than MOS cells and was also not as
sensitive to ZOL. When cells were incubated with 1mM of verapamil (m),
the ability of DOX and ZOL to inhibit the growth of the MOS/ADR cell
line became as sensitive as its parental MOS cell line. Furthermore, 10mM of
verapamil (&) strengthened the inhibitory effect of these agents on the
MOS/ADR cell line more than on the MOS cell line.
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resistant to DOX than its parental MOS cell line (Table 1,
Figure 1B). Similarly, MOS/ADR cells were not as sensitive to ZOL
as MOS cells (Figure 1C). The IC50 value of ZOL for the MOS/ADR
cells after 48h exposure was 7.10mM which was 4.6 times more
resistant to ZOL than parental MOS cells (Table 1). We next
examined the combined effects of a P-gp inhibitor, verapamil with
ZOL against P-gp-overexpressing MOS/ADR cells. Verapamil
(1mM) augmented the effects of ZOL on MOS/ADR cells and
restored the sensitivity of MOS/ADR cells almost same as of
parental MOS cells. Verapamil alone up to 30mM had no growth-
inhibitory effects on these cell lines (data not shown). These results
suggested that ZOL may be influenced by P-gp related multi-drug
resistance system in osteosarcoma cell lines.
Growth-inhibitory effects of other anticancer agents against
osteosarcoma cells are summarised in Table 1.
Concurrent combined effects of ZOL with other anticancer
agents
At first, we examined the combined effects of ZOL with commonly
used agents for osteosarcoma such as DOX, CDDP and MTX.
When combined with CDDP, the CIs at Fa 0.5 and Fa 0.8 were less
than 1.071 s.d. in both MOS and LM8 cells, except at Fa 0.5 for
LM8 cells, indicating that the effects of combination with CDDP
were synergistic rather than additive effects. DOX and MTX
additively augmented the effects of ZOL (Table 2). Next, we
explored the combined effects of ZOL with IM, PAC and GEM,
which were expected to be novel agents for osteosarcoma. IM also
showed additive effects with ZOL (Table 2). Interestingly, PAC and
GEM demonstrated significant synergistic effects with ZOL not
only in MOS and LM8, but also in P-gp-overexpressing cell line,
MOS/ADR (Table 2, Figure 2).
Sequential combined effects of ZOL with other anticancer
agents
Cytotoxic effects of DOX on both MOS (Figure 3A) and LM8 cells
(Figure 4A) and of CDDP on LM8 cells (Figure 4B) were
sinificantly enhanced by a 24h pretreatment with ZOL (Po0.05),
whereas the cytotoxic effects of MTX were antagonised by the ZOL
pretreatment of both osteosarcoma cell lines (Figures 3C and 4C).
Cytotoxic effects of PAC on both MOS (Figure 3E) and LM8 cells
(Figure 4E) and of GEM on LM8 cells (Figure 4F) were significantly
enhanced by a 24h pretreatment with ZOL (Po0.05), whereas the
cytotoxic effects of IM were affected significantly by ZOL
pretreatment, neither in MOS (Figure 3D) nor in LM8 cells
(Figure 4D).
Alterations of cell cycle by ZOL, PAC or GEM alone
As described above, the significant synergistic effects of PAC with
ZOL was seen in both MOS and LM8 cells, and those of GEM were
demonstrated only in LM8 cells. To investigate the possible
mechanisms underlying the synergistic interaction between ZOL
and PAC or GEM, we analysed the effects of these anticancer
agents on cell cycle. Alterations of cell cycle by 24h exposure to
ZOL, PAC or GEM in MOS and LM8 cells are summarised in
Table 3. After 24h exposure to ZOL at 2.0mM for MOS cells or at
15mM for LM8 cells, the percentages of cells in the S phase
increased without significant increase in the sub-G1 phase. After
24h exposure to PAC at 25nM for MOS or at 10nM for LM8 cells,
the percentages of cells in the G1 and S phases decreased and those
in the G2/M and sub-G1 phase increased. After 24h exposure to
25nM GEM, the percentages of cells in the S and G2 phases
decreased, and those in sub-G1 and G1 phases increased.
Combined effects of ZOL with PAC or GEM on the
alterations of cell cycle
When MOS cells were treated with 0.5mM ZOL combined with 5nM
PAC for 24h, there was an increase in the proportion of MOS cells
Table 1 The IC50
a values (mM) of ZOL and anticancer agents in murine
osteosarcoma cell lines
Agents YM529 ZOL DOX CDDP MTX IM PAC GEM
LM8 6.20 7.36 0.30 11.0 0.12 5.6 0.025 0.32
MOS 1.22 1.56 0.19 16.9 0.039 15.0 0.048 0.21
MOS/ADR 5.90 7.10 0.82 — — — 0.16 0.89
Resistance
b 4.8 4.6 4.4 — — — 3.3 4.2
Values represent the means of at least three independent experiments.
aIC50¼the
drug concentration yielding 50% growth inhibition.
bThe level of resistance to each
agent is expressed as the IC50 of MOS/ADR cells divided by the value of MOS cells.
YM529 data have been reported elsewhere (Horie et al, 2006).
Table 2 Combination indexes at Fa 0.50 and 0.80 of ZOL in concurrent
combination with other agents
Agents Cell line CI at Fa 0.5 (Effect) CI at Fa 0.8 (Effect)
DOX MOS 1.1470.09 (Antagonism) 0.9770.17 (Additive)
LM8 1.0170.14 (Additive) 0.5070.19 (Synergism)
CDDP MOS 0.3570.06 (Synergism) 0.5970.14 (Synergism)
LM8 0.8370.24 (Additive) 0.4870.13 (Synergism)
MTX MOS 1.5270.73 (Additive) 1.1570.92 (Additive)
LM8 0.9770.17 (Additive) 0.9370.31 (Additive)
IM MOS 0.1470.11 (Synergism) 0.7270.65 (Additive)
LM8 1.0670.19 (Additive) 1.2470.39 (Additive)
PAC MOS 0.0770.05 (Synergism) 0.2170.27 (Synergism)
LM8 0.0370.07 (Synergism) 0.5270.21 (Synergism)
GEM MOS 0.1870.10 (Synergism) 0.2670.31 (Synergism)
LM8 0.6770.12 (Synergism) 0.5370.22 (Synergism)
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Figure 2 Effect of the concurrent treatment with ZOL and anticancer
agents on murine osteosarcoma cell lines growth. The combination index
(CI) is plotted as a function of the fraction affected (Fa), which represents
the percentage of growth inhibition (e.g. 0.5¼50%) and was evaluated
using the MTT assay. Combinations of multiple equipotent agent
concentrations were analysed for synergistic (CIo1), additive (CI¼1), or
antagonistic (CI41) effects. Concurrent exposure to PAC (-1) and GEM
(-2) on LM8 cells (A), MOS cells (B) and MOS/ADR cells (C). Data are
presented as the mean7s.d. of three independent experiments.
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sin S-phase despite the fact that neither drug at this concentration
affected the cell cycle when used individually (Figure 5A-1-4).
These results are same as on LM8 cells treated with 10mM ZOL
combined with 5nM PAC for 24h (Figure 5B-1-4). These suggested
that when ZOL is combined with PAC, PAC might augment the
ability of ZOL to produce S-phase arrest. When LM8 cells were
treated with 10mM ZOL combined with 10nM GEM for 24h, there
was an increase in the ratio of LM8 cells in sub-G1, although
neither drug concentration produced this effect when applied by
itself (Figures 5B-2, 5 and 6). This indicated that when combined
with GEM, ZOL might augment the sub-G1 effect of GEM on the
cell cycle.
DISCUSSION
Our previous study revealed that when used as single agents, the
third-generation BPs, YM175 and YM529, possess antitumour
activity in an osteosarcoma cell line in vitro, and when these effects
were compared with the effect of BPs on other tumour cell lines,
YM175 and YM529 produce stronger antitumour effects on the
murine osteosarcoma cell line than other cancer cell lines.
However, the effects of YM175 and YM529 were impaired against
a P-gp-overexpressing osteosarcoma cell line (Horie et al, 2006).
As YM529 has not been made clinically available yet we
investigated the anti-osteosarcoma effects of ZOL, another third-
generation BP, which is clinically available and as potent as YM529
at inhibiting bone resorption in vivo (Widler et al, 2002).
To investigate specificity of ZOL against osteosarcoma cells, we
examined the inhibitory effects of ZOL against both osteosarcoma
cell lines and normal cells such as murine osteoblast and NHDF
cells. Moreover, to test the hypothesis that ZOL could have
chelating action, we examined the growth-inhibitory effects of the
most commonly used chelating agent EDTA on osteosarcoma cell
lines. Lower concentration of ZOL did not inhibit the growth of
normal cells, and 1000mM EDTA did not inhibit the growth of
osteosarcoma cells (Figure 1A). If the effect of ZOL depends on its
chelating mechanism, divalent cations can inhibit it. However, the
antiproliferative effect of ZOL was reported to be strengthened by
the addition of divalent cations, while that of EDTA was weakened
by the addition of divalent cations (Reinholz et al, 2000). These
findings suggest that ZOL selectively inhibited the growth of
osteosarcoma cells independently by its chelating effects.
The interaction between ZOL and P-gp is still controversial.
P-gp-overexpressing MOS/ADR cell line was 4.6 times more
resistant to ZOL than its parental MOS cell line (Table 1,
Figure 1C). Moreover, 1mM verapamil augmented the effects of
ZOL on MOS/ADR cells and restored the sensitivity of MOS/ADR
cells to almost same level of its parental cell line, MOS. These
findings suggested that the effects of ZOL in osteosarcoma cells
were affected by P-gp. However, we have previously reported that
the antitumour effects of ZOL against leukaemic cell lines are not
affected by P-gp (Kuroda et al, 2003). This discrepancy could be
explained by the differences on the activity of ZOL against
leukaemic cells and osteosarcoma cells. Both IC50s of ZOL against
parental and P-gp-overexpressing leukaemic cells are above 60mM,
whereas of those against osteosarcoma cells were much less. It
could, therefore, be argued that in the cell lines that we used, the
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Figure 3 Effect of sequential combinations of ZOL and anticancer
agents on MOS cell line growth. MOS cells were pretreated with 1.0mM
ZOL for 24h, washed thrice in PBS and then treated for 48h with the
second anticancer agents, namely, DOX (A), CDDP (B), MTX (C), IM
(D), PAC (E) or GEM (F). Data are presented as the mean7s.d. of three
independent experiments.
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Figure 4 Effect of sequential combinations of ZOL and anticancer
agents on LM8 cell line growth. LM8 cells were pretreated with 10mM ZOL
for 24h, washed thrice in PBS and then treated for 48h with the second
anticancer agents, namely, DOX (A), CDDP (B), MTX (C), IM (D), PAC
(E) or GEM (F). Data are presented as the mean7s.d. of three
independent experiments.
Table 3 Summary of cell cycle distribution (%) following 24h agent
treatment in osteosarcoma cells (A: MOS cells, B: LM8 cells)
Sub-G1 G1 SG 2/M
A-1: untreated MOS cells 3.7 46.2 30.8 16.8
A-2: ZOL (2.0mM) 5.5 32.1 46.3 12.6
A-3: PAC (25nM) 17.5 19.7 18.8 28.9
B-1: untreated LM8 cells 4.7 46.2 25.0 21.4
B-2: ZOL (15mM) 6.6 30.0 39.0 21.0
B-3: PAC (10nM) 27.0 2.4 10.2 47.0
B-4: GEM (25nM) 25.1 30.7 25.6 10.4
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sefflux pump enabled the elimination of small amounts of BPs,
although it did not work efficiently for large quantities of ZOL.
According to a previous study evaluating ZOL efficacy for the
treatment of osteoporosis (Chen et al, 2002), peak serum
concentrations were in the range of 1–3mM and maintained for
only a few hours. As IC50s of ZOL for MOS and LM8 cells are 1.56
and 7.36mM, respectively, it is likely that the effect of ZOL alone
might be insufficient. Moreover, ZOL is less effective against
P-gp-overexpressing osteosarcoma cells. Therefore, we examined
the combined effects of ZOL with other anticancer agents. In the
present study, we examine the combined effects of ZOL with
commonly used anti-osteosarcoma agents such as DOX, CDDP and
MTX. CDDP has been reported to augment synergistically the
effects of ZOL (Matsumoto et al, 2005). We also examine the
combined effects of ZOL with other three agents that are
undergoing clinical trial or have been examined in vitro
experiments for osteosarcoma cells, such as IM (McGary et al,
2002), PAC (Verweij et al, 2000) and GEM (Okuno et al, 2002). IM
specifically inhibits selected tyrosine kinase receptors, including
platelet-derived growth factor (PDGF) and c-Kit. As osteosarcoma
expresses low levels of c-Kit, but abundant levels of the PDGF
receptor (McGary et al, 2002), IM might be a promising candidate
for osteosarcoma therapeutics. Both PAC, a mitotic spindle toxin
and GEM, a nucleoside analogue, are in phase 2 clinical trails for
osteosarcoma (Verweij et al, 2000; Okuno et al, 2002).
The concurrent treatment of ZOL with DOX or CDDP resulted in
additive or synergistic growth inhibition of osteosarcoma cell lines.
Interestingly, concurrent exposure to ZOL significantly augmented
the effects of PAC and GEM in these cell lines. When MOS or LM8
cells were treated with ZOL combined with PAC for 24h, there was
an increase in the proportion of MOS cells in S-phase despite the
fact that neither drug at this concentration affected the cell cycle
when used individually (Figure 5A, B-1-4). These suggested that
when ZOL is combined with PAC, PAC might augment the ability
of ZOL to produce S-phase arrest, resulting the combined effects.
Similarly, when LM8 cells were treated with ZOL combined with
GEM at the concentration which had no effects on the alteration on
cell cycle for 24h, there was a significant increase in the ratio of
cells in sub-G1 (Figures 5B-2, 5 and 6). This indicated that when
combined with GEM, ZOL might induce more apoptotic cells.
These synergistic effects of ZOL depend on the doses and the
osteosarcoma cell line studied.
These results may have therapeutic application, particularly for
enhancing the efficacy of DOX or CDDP that cannot be
administered at higher dosages because of toxicity. Recently, the
combined effects of ZOL and PAC (Jagdev et al, 2001; Neville-
Webbe et al, 2006) or GEM (Budman and Calabro, 2006) have been
reported. However, the precise mechanism by which ZOL enhances
the effects of these agents is not yet fully understood. We tried to
investigate the mechanism of combined effects with ZOL and other
agents. As we have previously reported in leukaemic cells, ZOL
inhibited the progression of osteosarcoma cells in S-phase
(Table 3). Two agents that showed significant combined effects
with ZOL such as PAC and GEM revealed different effects of the
alteration of cell cycle in osteosarcoma cells. PAC accumulated
cells in G2/M phase, resulting the induction of apoptosis (Das et al,
2001), while GEM seemed to induce apoptosis in S phase (Shi et al,
2001) (Table 3). These findings suggest that it is difficult to predict
which agent becomes a good partner for ZOL based on its activity
on the alteration of cell cycle. Further studies will be required to
more fully elucidate these mechanisms.
P-gp-mediated multi-drug resistance is crucial for cancer
treatment. Although many P-gp inhibitors have been identified,
none of them have been proven clinically useful without side
effects, combination chemotherapy is one of the strategies to
overcome the P-gp mediated multi-drug resistance (Ozben, 2006).
Based on the additional effect of verapamil on the ZOL- or DOX-
induced growth inhibition of MOS/ADR cells (Figure 1B and C),
P-gp was suggested to have some role in ZOL-resistance. Because
PAC is a substrate for P-gp (Horwitz et al, 1993) (Table 1), it is
suggested that the coadministration of PAC and ZOL show the
inhibitory effect on the cell growth of MOS/ADR cells by similar
mechanism with the addition of verapamil. In the present study,
we have found the four-fold resistance against GEM in the MOS/
ADR cells in comparison with the parental cells (Table 1).
However, the additional effect of GEM on the ZOL-induced
inhibitory effect on cell growth was observed both in the parental
MOS and MOS/ADR cells (Figure 2B and C). Therefore, the
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Figure 5 Cell cycle analysis of combined treatment of ZOL with PAC or GEM. The effect of agents on the cell cycle was evaluated by flow cytometry of
osteosarcoma cells that had been exposed to different agent concentrations for 24h. MOS cells (A); untreated ( 1), 0.5mM ZOL ( 2), 5nM PAC ( 3),
0.5mM ZOL with 5nM PAC ( 4) and LM8 cells (B); untreated ( 1), 10mM ZOL (B-2), 5nM PAC ( 3), 10mM ZOL with 5nM PAC ( 4), 10nM GEM ( 5)
and 10mM ZOL with 10nM GEM ( 6). Cell cycle distribution (%) of each agent is shown. The data shown are representative of three independent
experiments.
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scoadministration of ZOL may independently inhibit the cell
growth of these cell lines in addition to GEM, which shows its
effects via deoxycytidine kinase pathway (Blackstock et al, 2001).
The mechanism of these combined effects should be more
investigated. However, ZOL plus PAC or GEM might become a
good application for multi-drug-resistant osteosarcoma cells.
We also investigated the sequential combined effects of ZOL
with other anticancer agents. MOS and LM8 cells were pretreated
for 24h with lower concentration of ZOL, and that concentration
did not alter the cell cycle and increase the percentage of apoptotic
cells in these cells, and significantly augmented the effects of DOX
in both MOS and LM8 cells (Figure 3A and 4A), and of CDDP in
LM8 cells (Figure 4B). In contrast, ZOL combined with MTX in
both cell lines showed antagonistic effects (Figure 3C and 4C). This
antagonistic effect of MTX was also seen in leukaemic cells
(Kimura et al, 2004). Because MTX activity was changed by the
sensitivity of cells and the pharmacokinetics of the drugs, MTX has
major cytotoxic effects on cells in the S phase and accumulates in
cells in the G1 to early S phase and later into the G2/M phase
(Lorico et al, 1990; Yamauchi et al, 2005). On the contrary, ZOL
has major cytotoxic effects in the S phase and accumulates in cells
in the late S and early G2 phases (Kuroda et al, 2003). If cells were
treated MTX followed by ZOL, the combined effect may be
observed to augment each other. But in the present study, the
combined treatments of ZOL with MTX have been carried out. It
has been noted that one agent might reduce the cytotoxicity of the
other agent by preventing cells from entering the specific phase in
which the cells are most sensitive to the other agent. Although the
reason for this antagonism is not fully clarified, the simultaneous
administration of ZOL with MTX might be counterproductive not
only for treatment of osteosarcoma but also for other cancers.
Methotrexate is commonly used in various chemotherapy regi-
mens (Kummel et al, 2006). Therefore, the clinical use of ZOL
should be evaluated carefully to avoid inadequate interaction even
when ZOL is indicated for other reasons, such as metastatic
involvement of the bone.
In conclusion, the combination of ZOL with DOX, CDDP, PAC
or GEM may be effective against murine osteosarcoma cells,
compared to the use of any of these agents alone. These results
provide a basis for conducting further studies using human
osteosarcoma cell lines or fresh osteosarcoma cells obtained from
patient resection samples and such studies ultimately will provide
a rationale for the preclinical/clinical evaluation of the antitumour
activity of ZOL in combination with other anticancer agents.
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